CD4 and melanoma: The Phase I study by Ott et al. of 20 predicted patient-specific neo-peptides plus TLR3, melanoma differentiation-associated protein 5 (MDA-5) and modified polyinosinic-polycytidylic acid (poly-ICLC) immunostimulants, with six stage IIIB/C and IVM1a/b untreated high-risk melanoma patients, resulted in all patients developing neoantigen-specific CD4+ and CD8+ polyfunctional T-cell responses, which were shown to distinguish between mutated and wild-type antigens [43].